Cipla

Deven Choksey recommended hold rating on Cipla with a target price of Rs 1570 in its research report dated September 08, 2025.

Buy Cipla; target of Rs 1754: Mirae Asset Sharekhan

Mirae Asset Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1754 in its research report dated September 02, 2025.

Trade Spotlight: How should you trade TCS, Exide Industries, Cipla, Max Financial Services, Hyundai Motor India, Nykaa, and others on August 26?

The market is likely to consolidate further until it decisively gets back above last Thursday's high. Below are some short-term trading ideas to consider.

Trade Spotlight: How should you trade DMart, Can Fin Homes, Radico Khaitan, Cipla, Dr Reddys Labs, Caplin Point, Afcons Infra, and others on August 22?

Overall, the trend remains favourable for bulls, despite the likelihood of intermittent consolidation. Below are some short-term trading ideas to consider.

Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports

The US government has long sought to shift pharmaceutical manufacturing back to domestic soil, citing both economic and national security concerns.

Buy Cipla; target of Rs 1800: ICICI Securities

ICICI Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1800 in its research report dated July 26, 2025.

Buy Cipla; target of Rs 1730: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated July 27, 2025.

Trade Spotlight: How should you trade TCS, Cipla, Torrent Pharma, NCC, Paytm, SBI Life Insurance, UPL, Syrma SGS Technology and others on July 29?

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas to consider.

Gainers & Losers: Top 10 stocks that moved the most on July 28

At close, the Sensex was down 572.07 points or 0.70 percent at 80,891.02, and the Nifty was down 156.10 points or 0.63 percent at 24,680.90. About 1207 shares advanced, 2766 shares declined, and 152 shares unchanged.

Cipla: Non-US markets to drive growth in the near term

Reduced contribution of Revlimid is likely to get offset by new products

Trade Spotlight: How should you trade Eternal, Cipla, Shyam Metalics, Torrent Pharma, Hubtown, Vimta Labs and others on July 28?

The market is expected to consolidate further as long as the frontline indices continue trading below their medium-term moving averages. Below are some short-term trading ideas to consider.

Gainers & Losers: Top 10 stocks that moved the most on July 25

About 1080 shares advanced, 2,771 shares declined, and 136 shares unchanged.

Cipla Q1 net profit beat estimates, jumps 10% to Rs 1,298 crore, revenue up 4%

Total revenue from operations rose 3.9 percent to Rs 6,957 crore in the period under review as compared with Rs 6,694 crore a year ago.

Cipla Q1FY26 preview: Margin pressure likely despite double-digit India growth

Cipla is expected to post muted profit growth for Q1FY26 despite steady revenue momentum, with US sales remaining flat and margin pressure weighing on the bottom line.

Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities

Net Sales are expected to increase by 1.8 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs 6,848.5 crore, according to ICICI Securities.

Morgan Stanley initiates coverage on pharma players, bullish only on Sun Pharma

Morgan Stanley sees earnings growth in the pharma sector moderating in FY25–27, though robust balance sheets could support investments in high-growth areas.

Aurobindo Pharma, Dr Reddy's, Lupin, other pharma stocks tumble up to 3% amid tariff jitters

'A renewed push for 'Buy America' could complicate matters for low-margin generics, and any uptick in regulatory stringency may weigh on sentiment,' said an analyst.

Trade Spotlight: How should you trade SBI Life, Federal Bank, CESC, Jubilant Foodworks, Carborundum Universal, Kolte-Patil Developers, and others on July 2?

The frontline indices are expected to see further consolidation in upcoming sessions before potentially entering a new leg of the uptrend. Below are some short-term trading ideas to consider.

Pharma stocks sharply tumble as Donald Trump says 'pharma tariffs coming very soon'; Granules, Lupin, Laurus Labs fall up to 4%

Pharma stocks: The Nifty Pharma index plunged nearly 2% to close as the top sectoral loser after Trump's statement.

Dr Reddy's, Laurus Labs, other pharma stocks jump up to 3% amid bullish brokerage calls, other triggers

The Nifty Pharma index is currently the top gaining sectoral index on NSE, rising over 1 percent to hover around 21,586.80.

Buy Cipla; target of Rs 1730 Prabhudas Lilladher

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated May 14, 2025.

Cipla: Largely unaffected by the Trump’s executive order

The medium-term growth drivers include the global rollout of respiratory and GLP-1 drugs.

Cipla shares weak despite Q4FY25 profit growth on caution over margin outlook: Should you buy, sell or hold?

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost of prescription medicines, will not impact Indian generic players.